iloprost and Neoplasm-Metastasis

iloprost has been researched along with Neoplasm-Metastasis* in 3 studies

Reviews

1 review(s) available for iloprost and Neoplasm-Metastasis

Article	Year
Mechanisms of the antimetastatic activity of stable prostacyclin analogues: modulation of host immunocompetence. Advances in prostaglandin, thromboxane, and leukotriene research, 1991, Volume: 21B Topics: Animals; Antineoplastic Agents; Epoprostenol; Iloprost; Immunocompetence; Melanoma, Experimental; Neoplasm Metastasis	1991

Other Studies

2 other study(ies) available for iloprost and Neoplasm-Metastasis

Article	Year
Antimetastatic action of stable prostacyclin analogs in mice. Advances in prostaglandin, thromboxane, and leukotriene research, 1991, Volume: 21B Topics: Animals; Antineoplastic Agents; Epoprostenol; Female; Iloprost; Mice; Neoplasm Metastasis; Platelet Aggregation	1991
Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation. Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:4 The antimetastatic effect of the antithrombotic agents exogenous prostacyclin (PGI2) and a synthetic analog, Iloprost, on experimental metastasis formation was studied by injecting BL6 melanoma cells into C57BL/6 mice. Suitable in vivo treatment conditions were selected according to the known properties of the two drugs, including their pharmacokinetics. Iloprost showed a greater ability to inhibit platelet aggregation induced by BL6 melanoma cells. PGI2 displayed a limited antimetastatic activity, largely dependent on the tumor cell load and treatment schedule. Iloprost showed a far superior activity, its antimetastatic effect lasting longer and remaining detectable up to 6 h after tumor cell inoculation. The present data complex provides further support to the concept of a crucial role for platelet-tumor cell interaction in the process of metastasis formation. Topics: Animals; Cell Line; Epoprostenol; Iloprost; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplastic Cells, Circulating; Platelet Aggregation	1988

Article

Year

Antimetastatic action of stable prostacyclin analogs in mice.

Advances in prostaglandin, thromboxane, and leukotriene research, 1991, Volume: 21B

Topics: Animals; Antineoplastic Agents; Epoprostenol; Female; Iloprost; Mice; Neoplasm Metastasis; Platelet Aggregation

1991

Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation.

Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:4

The antimetastatic effect of the antithrombotic agents exogenous prostacyclin (PGI2) and a synthetic analog, Iloprost, on experimental metastasis formation was studied by injecting BL6 melanoma cells into C57BL/6 mice. Suitable in vivo treatment conditions were selected according to the known properties of the two drugs, including their pharmacokinetics. Iloprost showed a greater ability to inhibit platelet aggregation induced by BL6 melanoma cells. PGI2 displayed a limited antimetastatic activity, largely dependent on the tumor cell load and treatment schedule. Iloprost showed a far superior activity, its antimetastatic effect lasting longer and remaining detectable up to 6 h after tumor cell inoculation. The present data complex provides further support to the concept of a crucial role for platelet-tumor cell interaction in the process of metastasis formation.

Topics: Animals; Cell Line; Epoprostenol; Iloprost; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplastic Cells, Circulating; Platelet Aggregation

1988